These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37843663)

  • 1. Relatlimab, an Immune Checkpoint Inhibitor that Blocks LAG-3, the Latest Drug to be Added to the Arsenal of Systemic Therapies for Melanoma: What Does a Surgical Oncologist Need to Know?
    van Akkooi ACJ
    Ann Surg Oncol; 2024 Jan; 31(1):1-3. PubMed ID: 37843663
    [No Abstract]   [Full Text] [Related]  

  • 2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
    Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
    N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma.
    Phillips AL; Reeves DJ
    Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab and relatlimab for the treatment of melanoma.
    Chen XY; Li YD; Xie Y; Cao LQ; Ashby CR; Zhao H; Chen ZS
    Drugs Today (Barc); 2023 Feb; 59(2):91-104. PubMed ID: 36811409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.
    Su D; Kluger H; Olino K
    Ann Surg Oncol; 2024 Mar; 31(3):1865-1879. PubMed ID: 37989956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Therapies for Melanoma.
    Buchbinder EI
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancement of anti-LAG-3 in cancer therapy.
    Li Y; Ju M; Miao Y; Zhao L; Xing L; Wei M
    FASEB J; 2023 Nov; 37(11):e23236. PubMed ID: 37846808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.
    Su J; Fu Y; Cui Z; Abidin Z; Yuan J; Zhang X; Li R; Zhao C
    Front Pharmacol; 2023; 14():1349081. PubMed ID: 38269271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant relatlimab and nivolumab in resectable melanoma.
    Amaria RN; Postow M; Burton EM; Tetzlaff MT; Ross MI; Torres-Cabala C; Glitza IC; Duan F; Milton DR; Busam K; Simpson L; McQuade JL; Wong MK; Gershenwald JE; Lee JE; Goepfert RP; Keung EZ; Fisher SB; Betof-Warner A; Shoushtari AN; Callahan M; Coit D; Bartlett EK; Bello D; Momtaz P; Nicholas C; Gu A; Zhang X; Korivi BR; Patnana M; Patel SP; Diab A; Lucci A; Prieto VG; Davies MA; Allison JP; Sharma P; Wargo JA; Ariyan C; Tawbi HA
    Nature; 2022 Nov; 611(7934):155-160. PubMed ID: 36289334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.
    Dimitriou F; Hauschild A; Mehnert JM; Long GV
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-22. PubMed ID: 35658500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients.
    Zaremba A; Eggermont AMM; Robert C; Dummer R; Ugurel S; Livingstone E; Ascierto PA; Long GV; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 Sep; 155():268-280. PubMed ID: 34392069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S; Shiraishi K; Mito T; Sayama K
    Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
    [No Abstract]   [Full Text] [Related]  

  • 13. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma.
    Albrecht LJ; Livingstone E; Zimmer L; Schadendorf D
    Curr Oncol Rep; 2023 Jun; 25(6):647-657. PubMed ID: 37004702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A decade of checkpoint inhibitors: current standard of care and future trends].
    Reischer A; Kruger S; von Bergwelt-Baildon M
    Dtsch Med Wochenschr; 2021 Sep; 146(17):1108-1118. PubMed ID: 34448187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab Plus Relatlimab: First Approval.
    Paik J
    Drugs; 2022 Jun; 82(8):925-931. PubMed ID: 35543970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age.
    Joshi K; Atwal D; Ravilla R; Pandey Y; Yarlagadda N; Kakadia S; Makhoul I; Hutchins L; Mahmoud F
    Perm J; 2020; 24():. PubMed ID: 32097116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview.
    Kejamurthy P; Devi KTR
    Med Oncol; 2023 Dec; 41(1):40. PubMed ID: 38158454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.
    Mesti T; Ceplak Mencin V; Mileva Boshkoska B; Ocvirk J
    Radiol Oncol; 2021 May; 55(3):354-361. PubMed ID: 33939899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?
    Abi-Aad SJ; Zouein J; Chartouni A; Naim N; Kourie HR
    Immunotherapy; 2023 Jun; 15(8):611-618. PubMed ID: 37009648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.